PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28369189-0	2017	Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir.	Raltegravir Potassium	153-164	major histocompatibility complex, class I, B	Homo sapiens	19-24	
32766769-1	2021	We present the first published case of raltegravir-associated drug-reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a child without characteristic human leukocyte antigen haplotypes HLA-B*57:01 or HLA-B*53:01.	Raltegravir Potassium	39-50	major histocompatibility complex, class I, B	Homo sapiens	217-222	
21126956-2	2010	METHODS: SHIELD is an ongoing 96-week pilot study of abacavir/lamivudine 600 mg/300 mg once daily with raltegravir 400 mg twice daily among HLA-B*5701-negative adults with screening viral load (VL) > 1,000 copies/mL.	Raltegravir Potassium	103-114	major histocompatibility complex, class I, B	Homo sapiens	140-145	
28369189-9	2017	Conclusions: These data implicate the prevalent African allele HLA-B*53:01 in the immunopathogenesis of raltegravir-induced DRESS syndrome.	Raltegravir Potassium	104-115	major histocompatibility complex, class I, B	Homo sapiens	63-68	
28369189-10	2017	Although the immunopathogenic mechanisms are currently unknown, virtual modeling suggests that raltegravir may bind within the antigen binding cleft of the HLA-B*53:01 molecule, but not within the closely related HLA-B*35:01 molecule.	Raltegravir Potassium	95-106	major histocompatibility complex, class I, B	Homo sapiens	156-161	
28369189-11	2017	Further studies are necessary to confirm the strength of the association between carriage of the HLA-B*53:01 allele and raltegravir-induced DRESS syndrome, and the potential utility of HLA screening before raltegravir treatment.	Raltegravir Potassium	120-131	major histocompatibility complex, class I, B	Homo sapiens	97-102	
24657622-0	2014	Raltegravir and elvitegravir-resistance mutation E92Q affects HLA-B*40:02-restricted HIV-1-specific CTL recognition.	Raltegravir Potassium	0-11	major histocompatibility complex, class I, B	Homo sapiens	62-67	
24657622-3	2014	We here investigated the effect of a raltegravir and elvitegravir-resistance mutation (E92Q) on HLA-B*40:02-restricted Int92-102 (EL11: ETGQETAYFLL)-specific CTLs.	Raltegravir Potassium	37-48	major histocompatibility complex, class I, B	Homo sapiens	96-101